Arrive AI and LifeSpan Pharmacy Drone Delivery LOI

On August 4, 2026, Arrive AI (NASDAQ:ARAI), an autonomous delivery network company, announced it had signed a non-binding letter of intent (LOI) with LifeSpan Pharmacy, LLC, an Indianapolis-based pharmacy provider, to explore developing and deploying an autonomous, drone-based pharmacy delivery network. The proposed program would pair licensed drone carriers with Arrive AI's patented Arrive Points, smart secure receiving stations that handle identity verification, chain of custody, temperature protection, and recipient notification. The initial phase is expected to include a live demonstration flight delivering actual pharmaceuticals, followed by pilot corridor buildout, expansion across priority delivery zones, and potential full deployment across LifeSpan's service area. The parties also intend to explore using autonomous ground robots for additional pharmacy use cases such as intra-facility medication transport, controlled-substance delivery, medical supply restocking, and specimen logistics. The LOI is non-binding, and the parties will collaborate on program planning, site assessment, and regulatory pathway coordination before deciding whether to proceed to a definitive agreement. Arrive AI does not manufacture drones but provides the software intelligence and physical infrastructure for autonomous delivery. LifeSpan Pharmacy is a division of Grant Cardone.